Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Free Cash Flow: 2020-2024

Historic Free Cash Flow for ARS Pharmaceuticals (SPRY) over the last 5 years, with Dec 2024 value amounting to $13.0 million.

  • ARS Pharmaceuticals' Free Cash Flow fell 184.29% to -$41.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.0 million, marking a year-over-year decrease of 86.87%. This contributed to the annual value of $13.0 million for FY2024, which is 121.85% up from last year.
  • Per ARS Pharmaceuticals' latest filing, its Free Cash Flow stood at $13.0 million for FY2024, which was up 121.85% from -$59.4 million recorded in FY2023.
  • Over the past 5 years, ARS Pharmaceuticals' Free Cash Flow peaked at $13.0 million during FY2024, and registered a low of -$59.4 million during FY2023.
  • Its 3-year average for Free Cash Flow is -$28.9 million, with a median of -$40.3 million in 2022.
  • Per our database at Business Quant, ARS Pharmaceuticals' Free Cash Flow crashed by 128.64% in 2022 and then spiked by 121.85% in 2024.
  • ARS Pharmaceuticals' Free Cash Flow (Yearly) stood at -$32.1 million in 2020, then spiked by 45.14% to -$17.6 million in 2021, then crashed by 128.64% to -$40.3 million in 2022, then crashed by 47.58% to -$59.4 million in 2023, then skyrocketed by 121.85% to $13.0 million in 2024.